Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Entera Bio (ENTX – Research Report). The associated price target is $10.00.
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily focusing on Entera Bio’s strategic collaboration with OPKO Health. This partnership is set to advance the development of an oral dual agonist GLP-1/glucagon peptide, which is a promising treatment for obesity and related disorders. The collaboration not only provides Entera Bio with access to a potentially lucrative market but also ensures shared development costs, with Entera holding a significant ownership stake in the program.
Additionally, the recent positive pharmacokinetic results for Entera’s oral oxyntomodulin tablet program, which showed favorable systemic exposure and bioavailability, further strengthen the company’s position. The anticipated FDA ruling on the SABRE ASBMR-FNIH regulatory endpoint for osteoporosis drugs is also expected to be a significant catalyst for Entera Bio’s EB613 program, potentially advancing it into pivotal development. These factors collectively contribute to Selvaraju’s positive outlook and Buy rating for Entera Bio.